6-APDB
6-APDB is a dihydrobenzofuran entactogen, the 2,3-dihydro analogue of 6-APB and a close relative of MDA. It acts as a serotonin-preferring monoamine releaser. Human data is minimal, limited to user reports and structural inference.
01 Overview
6-APDB (6-(2-aminopropyl)-2,3-dihydrobenzofuran), sometimes called 4-Desoxy-MDA, is a saturated-ring analogue of 6-APB. In vitro it is a relatively serotonin-selective releaser, which is thought to bias effects toward the entactogenic rather than stimulant end.
No clinical studies exist. Its risk profile is extrapolated from its serotonergic mechanism and reports from the research-chemical community; reduced 5-HT2B activity relative to the benzofuran parents has been suggested but not established in humans.
02 Mechanism
Releases serotonin, norepinephrine and dopamine with relative serotonin selectivity; entactogen-type mechanism analogous to MDA.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 40–70 mg | Oral | User-reported only. |
| Common | 70–110 mg | Oral | Long duration reported, similar to 6-APB. |
| Strong | 110–140 mg | Oral | Serotonergic and thermal risk rises. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Entactogenic empathyEmotional openness and warmth with less stimulation than 6-APB. | Anecdotal | ||
| Mood elevationEuphoria and increased sociability. | Anecdotal | ||
| Long durationExtended effect window per user reports. | ~6-10 h | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| NeurotoxicitySerotonergic neurotoxicity is plausible by analogy to MDA/MDMA but UNCONFIRMED for 6-APDB. | Moderate | Unknown in humans | Unconfirmed | |
| HyperthermiaOverheating plausible given serotonergic mechanism. | Severe | Uncommon; dose- and setting-dependent | Anecdotal | |
| Serotonin syndromeTheoretical based on mechanism; not well documented for this specific compound. | Life-threatening | Rare alone; higher with serotonergic co-use | Unconfirmed |